These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16542137)

  • 1. Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis.
    Brod SA; Nguyen M; Hood Z; Shipley GL
    J Interferon Cytokine Res; 2006 Mar; 26(3):150-5. PubMed ID: 16542137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon beta-1a induces tumor necrosis factor receptor 1 but decreases tumor necrosis factor receptor 2 leukocyte mRNA levels in relapsing-remitting multiple sclerosis.
    Reuss R; Pohle S; Retzlaff K; Hemberger J; Oschmann P
    Neuroimmunomodulation; 2009; 16(3):171-6. PubMed ID: 19246939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis.
    Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Bornstein NM; Karni A
    J Neuroimmunol; 2011 Mar; 232(1-2):171-8. PubMed ID: 21111488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ingested type I interferon: a potential treatment for autoimmunity.
    Brod SA
    J Interferon Cytokine Res; 2002 Dec; 22(12):1153-66. PubMed ID: 12581487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS.
    Brod SA; Lindsey JW; Vriesendorp FS; Ahn C; Henninger E; Narayana PA; Wolinsky JS
    Neurology; 2001 Sep; 57(5):845-52. PubMed ID: 11552015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.
    Reder AT; Velichko S; Yamaguchi KD; Hamamcioglu K; Ku K; Beekman J; Wagner TC; Perez HD; Salamon H; Croze E
    J Interferon Cytokine Res; 2008 May; 28(5):317-31. PubMed ID: 18547162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
    van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
    Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ingested interferon alpha induces Mx mRNA.
    Brod SA; Nelson L; Jin R; Wolinsky JS
    Cytokine; 1999 Jul; 11(7):492-9. PubMed ID: 10419650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A.
    Sarchielli P; Critelli A; Greco L; Sokola E; Floridi A; Gallai V
    Cytokine; 2001 Jun; 14(5):294-8. PubMed ID: 11444910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.
    Gilli F; Marnetto F; Caldano M; Sala A; Malucchi S; Capobianco M; Bertolotto A
    Mult Scler; 2006 Feb; 12(1):47-57. PubMed ID: 16459719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy.
    Antonelli G; Simeoni E; Turriziani O; Tesoro R; Redaelli A; Roffi L; Antonelli L; Pistello M; Dianzani F
    J Interferon Cytokine Res; 1999 Mar; 19(3):243-51. PubMed ID: 10213463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function.
    Durelli L; Bongioanni MR; Cavallo R; Ferrero B; Ferri R; Verdun E; Bradac GB; Riva A; Geuna M; Bergamini L
    Mult Scler; 1995; 1 Suppl 1():S32-7. PubMed ID: 9345396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MxA gene expression in peripheral blood mononuclear cells from patients infected chronically with hepatitis C virus treated with interferon-alpha.
    Meier V; Mihm S; Ramadori G
    J Med Virol; 2000 Nov; 62(3):318-26. PubMed ID: 11055241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis.
    van der Voort LF; Visser A; Knol DL; Oudejans CB; Polman CH; Killestein J
    Eur J Neurol; 2009 Sep; 16(9):1049-52. PubMed ID: 19486142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment strategies for early-stage chronic lymphocytic leukemia: can interferon-inducible MxA protein and tumor necrosis factor play a role as predictive markers for response to interferon therapy?
    Bezares F; Kohan S; Sacerdote de Lustig E; Farías E; Murro H; Horisberger MA
    J Interferon Cytokine Res; 1996 Jul; 16(7):501-5. PubMed ID: 8836914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis.
    Brod SA; Kerman RH; Nelson LD; Marshall GD; Henninger EM; Khan M; Jin R; Wolinsky JS
    Mult Scler; 1997 Feb; 3(1):1-7. PubMed ID: 9160341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
    Weber F; Polak T; Günther A; Kubuschok B; Janovskaja J; Bitsch A; Poser S; Rieckmann P
    Ann Neurol; 1998 Jul; 44(1):27-34. PubMed ID: 9667590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
    Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers.
    Khademi M; Bornsen L; Rafatnia F; Andersson M; Brundin L; Piehl F; Sellebjerg F; Olsson T
    Eur J Neurol; 2009 Apr; 16(4):528-36. PubMed ID: 19220425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interferon-alpha2b recombinant improved the cognitive dysfunction in patients with relapsing remitting multiple sclerosis].
    Cabrera-Gómez JA; Echazábal-Santana N; Porrero-Martín P; Valenzuela-Silva C; Rodríguez CA; Fuentes-Suárez I; Pérez-Ruiz L; Ramos-Cedeño AM; Cabrera-Núñez JA;
    Rev Neurol; 2003 Aug 1-15; 37(3):214-20. PubMed ID: 12938052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.